What This Signal Is (Quick)
This is the Aggressive Momentum flavor of the Momentum Swing scanner. It is designed to hunt for stocks that are already running hard and are being pushed by strong institutional participation: high momentum, high volume, and high volatility all at once.
The signal is a breakout continuation setup. We are not buying dips here – we are looking for names pressing up near their highs, with volume running well above normal and price trending strongly above key moving averages. The intended holding window is short to medium term, roughly one to four weeks, and the risk level is explicitly high. This is an experimental scanner , not a polished production model.
In other words: this screen is meant for traders who are comfortable with fast moves, gap risk, and sharp reversals, and who use strict risk management and clear exit rules.
How We Ranked Today (Reader Version)
For November 21, 2025, the Aggressive Momentum screen surfaced one qualifying symbol :
- EXAS (Exact Sciences Corporation) in the Healthcare sector.
The strategy-level guidance recommends ranking by the composite score (0–1), with RSI as a global default where available, and falling back to liquidity measures like adv20 when RSI is absent. For today’s run:
- Only one symbol passed all filters, so it is effectively ranked first by default.
- Liquidity is exceptionally strong: EXAS trades roughly 700 million USD in 20-day average dollar volume.
- Volume thrust today is more than 2.3 times the 20-day norm, which is a textbook aggressive momentum characteristic.
Overlays used in the interpretation:
- Insider flows over the last 90 days (net buying vs selling).
- Days to the next earnings event.
- Analyst coverage and forward estimates.
- Overall market context from the indices , VIX , yields , and crypto.
Signals are provided for educational use and back-testing , not as trade recommendations.
Today’s Top Signal Table
Single-signal day, sorted by the strategy’s composite ranking framework and liquidity characteristics.
| Rank | Ticker | Company | Sector | Last ($) | Vol Thrust | % of 52W High | Score (0–100) | Market Cap | Insider Net (USD, 90d) | Days → Earnings |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EXAS | Exact Sciences Corporation | Healthcare | 100.90 | 2.37x | 100% | 0 | 19.1B | -$1.3M | 89 |
Key numeric notes based on your data:
- EXAS closed at 100.90 USD , sitting right at 100 percent of its 52-week high.
- Volume thrust ≈ 2.37x , meaning volume is over 130 percent above its 20-day average.
- Market cap is roughly 19.1 billion USD.
- Composite score is currently 0 on a 0–1 scale (0–100 after scaling). That reflects the model’s present calibration rather than the absence of momentum in price.
Insider activity:
- Over the past 90 days, your insider file shows only sales transactions (S) and no open-market purchases.
- Aggregating purchases minus sales per your rules, EXAS shows about 1.30 million USD in net insider selling , a mild bearish overlay that does not negate the technical breakout but adds caution on the fundamental sentiment side.
Earnings calendar:
- Next earnings for EXAS in your calendar are scheduled for 2026-02-18 after market close (amc) , about 89 days after the 2025-11-21 signal date.
- That places earnings in the “distant event risk” bucket: not an immediate catalyst for this 1–4 week swing window, but relevant for anyone considering holding longer.
Analyst estimates:
- For the nearest fiscal year in your estimates file (ending 2025-12-31), consensus EPS is still negative (around -0.70 USD), with eight analysts contributing to the forecast and revenue estimates in the low-to-mid billions.
- Out in later years (2026 and beyond), average EPS estimates turn positive and trend higher, suggesting a transition story where the market is increasingly pricing in improving profitability rather than current earnings alone.
Field Notes
Some quick context on why EXAS is being picked up by an Aggressive Momentum screen:
- Strong momentum and trend structure
- Price is sitting at new 52-week highs.
- The short and medium moving averages from your file (ma10, ma21, ma50, ma200) show price extended well above the 50-day and 200-day lines, consistent with a powerful upside trend rather than a mean-reversion zone.
- Volume and liquidity
- Volume thrust above 2.3x is exactly what you would want to see in an aggressive breakout: it implies broad participation and potential institutional involvement rather than a thin, retail-only spike.
- Liquidity, measured by adv20_dollars ≈ 700M USD , makes it more practical for larger swing positions and reduces some execution risk.
- Volatility profile
- Your vol63 metric is elevated, which is expected in this strategy: the scanner is explicitly looking for high volatility names where price can move meaningfully over a one to four week window, at the cost of larger drawdowns if the move fails.
- Fundamental and insider overlays
- The insider tape is net negative ~1.3M USD over the last 90 days, driven by open-market sales. That is not unusual after a strong run, but it is still a soft yellow flag.
- Analyst consensus in your estimates file points to improving medium-term EPS trajectory , even though near-term EPS remains negative. This is typical of growth diagnostics stories where the market cares as much about future cash flows and strategic positioning as about current earnings.
- News catalyst backdrop
- Recent news flow has been dominated by Abbott’s move to acquire Exact Sciences in a cash deal around 105 USD per share , valuing the company at roughly 21–23 billion USD including debt , according to the companies’ joint press release and subsequent coverage. (Reuters)
- Headlines from multiple outlets highlight EXAS as a leader in cancer screening and precision oncology diagnostics, with products like Cologuard and Oncotype DX forming the strategic rationale for the deal. (Reuters)
- This sort of large, strategic acquisition is exactly the kind of catalyst that can turbo-charge a momentum setup, but it also changes the risk profile: price action may increasingly be anchored by the deal terms rather than pure technicals.
Taken together, EXAS fits the template of a high-liquidity, high-volatility breakout name that has just been hit by a major corporate event.
Vlad’s Take (EverHint)
Today’s market backdrop, as of November 21, 2025:
- The S &P 500 gained about 0.7 percent , the Nasdaq Composite about 0.5 percent , and the Dow Jones Industrial Average nearly 1.0 percent , while the Russell 2000 small-cap index popped roughly 2.7 percent. That points to a risk-on tone with small caps leading , which generally supports momentum swing setups.
- The VIX closed near 23.4 , down almost 10 percent on the day, but still in the elevated volatility zone rather than calm conditions. Treasury yields, via the 10-year (TNX), eased slightly, while Bitcoin and Ethereum pulled back around 1.5–2.2 percent.
Given this backdrop, the Aggressive Momentum screen landing on a single name like EXAS makes intuitive sense: the market environment is supportive of risk, small caps are outperforming, and one high-profile corporate event is sucking in a lot of attention and volume.
From a practical trading standpoint:
- EXAS is trading right at its 52-week highs , on 2.3x volume , after a big M&A headline. That is the textbook definition of a crowded, high-energy tape.
- The upside narrative is clear: strategic acquisition, long runway in cancer diagnostics, improving forward estimates, and a strong technical trend.
- The risk side is equally clear: deal uncertainty, headline risk, notable insider selling over the last quarter, and the possibility that price spends time chopping around the deal price rather than trending cleanly.
For an aggressive swing trader, this kind of setup usually calls for:
- Tighter stops and smaller position sizing than a normal momentum trade, given the elevated VIX and corporate event risk.
- A clear time horizon: once the post-deal volatility fades or the price action starts to compress near the offer price, the edge for this strategy diminishes quickly.
- Zero expectation that this is “safe” money – it is a deliberately high-risk, high-reward niche inside your broader toolkit.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
No comments:
Post a Comment